A risk-benefit assessment of anti-obesity drugs

Drug Safety

Volumn 20, Issue 2, 1999, Pages 119-131

  Kolanowski, Jaroslaw ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; PHENTERMINE; PHENYLPROPANOLAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH HAZARD; HUMAN; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CARDIOVASCULAR SYSTEM; HUMANS; OBESITY; RISK ASSESSMENT;

EID: 0032990098     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920020-00003     Document Type: Article

References (65)

1. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647-57
2. Pi-Sunyer X. The NAASO position paper on approval and use of drugs to treat obesity. Obes Res 1995; 3 (5): 471-2
3. Guidelines for the approval and use of drugs to treat obesity: a position paper of the North American Association for the Study of Obesity. Obes Res 1995; 3 (5): 473-8
4. Bray GA. Evaluation of drugs for treating obesity. Obes Res 1995; 3 Suppl. 4: 425S-34S
5. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276 (23): 1907-15
6. Mezitis SGE, Aronne LJ. Pharmacotherapy of obesity. Curr Opin Endocrinol Diabet 1997; 4: 407-11
7. Bray GA. Pharmacological treatment of obesity. In: Bray GA, Bouchard J, James WPT, editors, Handbook of obesity. New York: Marcel Dekker, 1998: 953-75
8. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 2207-12
9. Manson JE, Faith GA. Pharmacotherapy for obesity - do the benefits outweigh the risk? N Engl J Med 1996; 335 (9): 659-60
10. Seidel JC. Time trends in obesity: an epidemiological perspective. Horm Metab Res 1997; 29: 155-8
11. Blundell JE, Halford CG. Pharmacological aspects of obesity treatment: towards the 21st century. Int J Obesity 1995; 19 Suppl. 3: S51-5
12. Abenheim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335 (9): 609-16
13. Conolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337 (9): 581-8
14. Wellman PJ. Overview of adrenergic anorectic agents. Am J Clin Nutr 1992; 55 Suppl. 1: 193S-9S
15. Silverstone JT, Solomon T. The long-term management of obesity in general practice. Br J Clin Pract 1965; 19: 395-8
16. McKay RHG. Long-term use of diethyproprion in obesity. Curr Med Res Opin 1973; 1: 489-93
17. Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968; 1: 352-4
18. Inoue S. Clinical studies with mazindol. Obes Res 1995; 3 Suppl. 4: 549S-52S
19. Greenway FL. Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr 1992; 55 Suppl. 1: 203S-5S
20. Schteingart DE. Effectiveness of phenylpropanolamine in the management of moderate obesity. Int J Obes 1992; 16: 487-93
21. Morgan JP, Funderburk FR. Phenylpropanolamine and blood pressure: a review of prospective studies. Am J Clin Nutr 1992; 55 Suppl. 1: 206S-10S
22. Munro JF, Scott C, Hodge J. Appraisal of the clinical value of serotoninergic drugs. Am J Clin Nutr 1992; 55 Suppl. 1: 189S-92S
23. Turner P. Benefit:risk consideration in long-term therapy with dexfenfluramine. Int J Obes 1992; 16 Suppl. 3: S15-7
24. Kolanowski J, Younis LT, Vanbutsele R, et al. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. Eur J Clin Pharmacol 1992; 42: 599-606
25. Scheen AJ, Paolisso G, Salvatore T, et al. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care 1991; 14 (4): 325-32
26. Finer N, Finer S, Naoumova RP. Prolonged use of very low calorie diet (Cambridge Diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine. Int J Obes 1989; 13 Suppl. 2: 91-3
27. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 11: 1142-5
28. Darga LL, Carrol-Michals L, Botsford SJ, et al. Fluoxetines effect on weight loss in obese subjects. Am J Clin Nutr 1991: 54 (2): 321-5
29. Goldstein DJ, Rampey AH, Jr, Roback PJ, et al. Efficacy and safety of long-term fluoxetine treatment of obesity - maximizing success. Obes Res 1995; 3 Suppl. 4: 481S-90S
30. Daubresse JC, Kolanowski J, Krzentowski G, et al. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996. 4 (4): 391-6
31. Weintraub M, Hasday JD, Mushlin AI, et al. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984; 144 (6): 1143-8
32. Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51 (5): 586-94
33. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther 1992; 51 (5): 595-601
34. Atkinson RL, Blank RC, Loper JF, et al. Combined drug therapy of obesity, Obes Res 1995; 3 Suppl. 4: 497S-500S
35. Atkinson RL, Blank RC, Schumacher D, et al. Long-term drug treatment of obesity in a private practice setting. Obes Res 1997; 5 (6): 578-86
36. Pedrinola F, Sztejnsznajd C, Lima N, et al. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 1996; 4 (6): 549-54
37. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13 (2): 94-104
38. Astrup A, Breum L, Tourbo S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes 1992; 16: 269-77
39. Astrup A, Breum L, Tourbo S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res 1995; 3 Suppl. 4: 537S-40S
40. Gurtner HP. Aminorex and pulmonary hypertension. Cor Vasa 1985; 27: 60-171
41. Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337 (9): 602-5
42. Schembre DB, Boynton KK. Appetite-suppressant drugs and pulmonary hypertension [letter]. N Engl J Med 1997; 336 (7): 510-1
43. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine [letter]. N Engl J Meal 1997; 337 (9): 635
44. Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine [letter]. N Engl J Med 1997; 337 (9): 636
45. Bowen R, Glicklich A, Khan K, et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. US Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 1061-6
46. Wadden TA, Berkowitz RI, Silvestry F, et al. The Fen-Phen Finale: a study of weight loss and valvular heart disease. Obes Res 1998; 6 (4); 278-84
47. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. N Engl J Med 1998; 339 (11): 713-8
48. Jick H, Vasilaskis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med; 339 (11): 719-24
49. Weissman NJ, Tighe JF, Gottdiener, et al. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained release dexfenfluramine, or placebo. N Engl J Med; 339 (11): 725-32
50. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54
51. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 1997; 21 Suppl. 1: S25-9
52. Rolls BJ, Shide DJ, Thorwert ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6 (1): 1-11
53. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998; 6 (2): 115-21
54. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4 (3): 263-70
55. Lean MEJ. Sibutramine - a review of clinical efficacy. Int J Obes 1997; 21 Suppl. 1: S30-6
56. Wynne RD, Braybrooke RM, Brown T, et al. A single-dose, placebo-controlled, comparative evaluation of the cardiovascular effects of sibutramine and aminotriptiline in normal volunteers. Int J Pharm Med 1997; 11: 65-70
57. Drent ML, van der Veen LA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes 1993; 17: 241-4
58. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3: S12-23
59. James WPT, Avenell A, Broom J, et al. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997; 21 Suppl. 3: S24-30
60. Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev 1997; 5: 83-103
61. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-73
62. Van Gaal LF, Broom JI, Enzi G, el al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6 month dose ranging study. Eur J Clin Pharmacol 1998; 54: 125-32
63. Hollander PA, Elbein SC, Hirsch IB. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21 (8): 1288-94
64. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119 (7 Pt 2): 707-13
65. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obes Res 1995; 3 Suppl. 4: 491S-6S